Boston Scientific Corp (BSX) reports impressive Q4 2024 results with 22.4% revenue growth and a 26% increase in adjusted EPS, ...

Most people aren’t aware of the symptoms, especially if they’re otherwise healthy, because they don’t know that AFib can affect anyone!

The company expects its 2025 adjusted earnings to be in the range of $2.80 to $2.87 per share, above analysts' average ...

Securities adjusted its outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $130 from $110 while ...

Climbing sales for a made-in-Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company brushed off tariffs. The medtech company’s pulse ...

As pulsed field ablation transformed the electrophysiology market over the last year, Boston Scientific Corp. emerged as the ...